Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas

PROGRAM DESCRIPTION
The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

The CME program, Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas, will provide oncologists with current guideline-based diagnostic, staging, and treatment strategies for patients with advanced BCC and CSCC as well as how newly approved and agents in development fit into treatment strategies.

AGENDA
Welcome and Introductions
Evidence-based Diagnosis and Staging of Advanced Nonmelanoma Skin Cancers
Current and Emerging Therapies for Treating Advanced BCC and CSCC
Q&A Session and Activity Roundup

PROGRAM FACULTY AND STEERING COMMITTEE

Roman Groisberg, MD
Assistant Professor,
Medical Oncology Department of Melanoma and Sarcoma Rutgers
Cancer Institute of New Jersey
New Brunswick, NJ

Max Lenowitz, CRNP
Jefferson Medical Oncology
Philadelphia, PA

Melissa Wilson, MD, PhD
Medical Oncology Fellowship
Program Director/Melanoma Program
Director St. Luke’s Cancer
Center – St. Luke’s University Health
NetworkEaston, PA

TARGET AUDIENCE
The intended audience for this educational initiative is oncologists, oncology nurses, and other clinicians who are responsible for the diagnosis and management of patients with advanced NMSC (Non-Melanoma Skin Cancer).

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to:

• Make timely diagnoses of patients with BCC or CSCC using current evidence-based criteria
• Accurately stage and risk stratify patients with BCC or CSCC to establish optimal follow-up regimens
• Make evidence-based treatment selections for patients with advanced BCC or CSCC
• Assess the safety and efficacy of emerging therapies for advanced BCC or CSCC

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN DESIGNATION CREDIT STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/MOC/MIPS credit or the evaluation, please email contact@potomacme.org.

ABIM MOC DESIGNATION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

MOC APPROVAL STATEMENT

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, “Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Family Medicine

NURSING ACCREDITATION AND DESIGNATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Rockpointe Corporation. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES (ANCC)
Amedco LLC designates this activity for a maximum of 1 ANCC contact hour.

Click here to download nursing learner notification.

MIPS CREDIT DESIGNATION

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.

DISCLOSURE INFORMATION
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

Program Faculty and Steering Committee
The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:

Roman Groisberg, MD: Consultant/Independent Contractor: GLG; Grant/Research Support: Bristol Myers Squibb, Merck, Philogen, Regeneron, Roche/Genentech; Speaker’s Bureau: Deciphera

Max Lenowitz, CRNP: Nothing to disclose

Melissa Wilson, MD, PhD: Honoraria: Eisai

Planners and Managers
The planners and mangers reported the following relevant financial relationships with ineligible companies:

Chad Williamson, MS, MBA, CMPP: Nothing to disclose

Content Reviewers
The content reviewers reported the following relevant financial relationships with ineligible companies:

Katie Propst, PhD: Nothing to disclose

FDA DISCLOSURE
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

HARDWARE/SOFTWARE REQUIREMENTS
Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/ANCC/MIPS CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC/ANCC/MIPS activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Nursing Credit provided by Amedco.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Click here for the PCME Privacy Policy